Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADM2 | Q7Z4H4 | 14/20 | 0.50 |
| ▸ | CALCB | P10092 | 14/20 | 0.48 |
| ▸ | CALCRL | Q16602 | 5/20 | 0.45 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10193456 | 0.90 | ADM2 (0.51) | ADM2CALCBCALCRLRAMP1 | |
| SCHEMBL3047341 | 0.90 | ADM2 (0.48) | ADM2CALCBCALCRLRAMP1 | |
| SCHEMBL3045683 | 0.90 | ADM2 (0.50) | ADM2CALCBCALCRLRAMP1 | |
| SCHEMBL550131 | 0.88 | ADM2 (0.60) | ADM2CALCBCALCRL | |
| SCHEMBL3036259 | 0.85 | ADM2 (0.50) | ADM2CALCBCALCRL | |
| Hydrochloric Acid SCHEMBL548949 | 0.84 | ADM2 (0.49) | ADM2CALCBCALCRL | |
| SCHEMBL3049124 | 0.83 | CALCB (0.47) | ADM2CALCBCALCRL | |
| SCHEMBL549047 | 0.83 | ADM2 (0.48) | ADM2CALCBCALCRL | |
| SCHEMBL3051523 | 0.81 | ADM2 (0.46) | ADM2CALCBCALCRL | |
| SCHEMBL3034499 | 0.81 | ADM2 (0.58) | ADM2CALCBCALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225227-B1 | 1',3'-Dihydrospiro[imidazolidin-4,2'-inden]-2,5-diones and 1,3-dihydrospiro[inden-2,3']-pyrroles as CGRP antagonists | BOEHRINGER INGELHEIM INT (DE) | 2015-08-26 | — | — | EP | disclosed |
| US-8110575-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| US-8110575-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| US-8110575-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| US-20110021500-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021500-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021500-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2251339-A2 | COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021500-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, CALCA | ADM2 245/4885CALCB 9/4885CALCRL 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.